Leukemia . COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

[tetano]

Leukemia


. 2021 Nov 1.
doi: 10.1038/s41375-021-01450-8. Online ahead of print.
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study


Thomas Chatzikonstantinou ^{# 1 2} , Anargyros Kapetanakis ^{# 2} , Lydia Scarfò ^{# 3} , Georgios Karakatsoulis ^{2 4} , David Allsup ⁵ , Alejandro Alonso Cabrero ^{6 7} , Martin Andres ⁸ , Darko Antic ^{9 10} , Mónica Baile ¹¹ , Panagiotis Baliakas ^{12 13} , Dominique Bron ¹⁴ , Antonella Capasso ¹⁵ , Sofia Chatzileontiadou ¹⁶ , Raul Cordoba ¹⁷ , Juan-Gonzalo Correa ¹⁸ , Carolina Cuéllar-García ¹⁹ , Lorenzo De Paoli ²⁰ , Maria Rosaria De Paolis ²¹ , Giovanni Del Poeta ²² , Christos Demosthenous ¹ , Maria Dimou ²³ , David Donaldson ²⁴ , Michael Doubek ²⁵ , Maria Efstathopoulou ²⁶ , Barbara Eichhorst ²⁷ , Shaimaa El-Ashwah ²⁸ , Alicia Enrico ²⁹ , Blanca Espinet ³⁰ , Lucia Farina ³¹ , Angela Ferrari ³² , Myriam Foglietta ³³ , Henrik Frederiksen ³⁴ , Moritz Fürstenau ²⁷ , José A García-Marco ³⁵ , Rocío García-Serra ^{36 37} , Massimo Gentile ³⁸ , Eva Gimeno ³⁹ , Andreas Glenthøj ⁴⁰ , Maria Gomes da Silva ⁴¹ , Odit Gutwein ^{42 43} , Yervand K Hakobyan ⁴⁴ , Yair Herishanu ⁴⁵ , José Ángel Hernández-Rivas ⁴⁶ , Tobias Herold ⁴⁷ , Idanna Innocenti ⁴⁸ , Gilad Itchaki ⁴⁹ , Ozren Jaksic ⁵⁰ , Ann Janssens ⁵¹ , Оlga B Kalashnikova ⁵² , Elżbieta Kalicińska ⁵³ , Linda Katharina Karlsson ⁴⁰ , Arnon P Kater ⁵⁴ , Sabina Kersting ⁵⁵ , Jorge Labrador ⁵⁶ , Deepesh Lad ⁵⁷ , Luca Laurenti ^{48 58} , Mark-David Levin ⁵⁹ , Enrico Lista ⁶⁰ , Alberto Lopez-Garcia ¹⁷ , Lara Malerba ⁶¹ , Roberto Marasca ⁶² , Monia Marchetti ⁶³ , Juan Marquet ⁶⁴ , Mattias Mattsson ^{12 65} , Francesca R Mauro ⁶⁶ , Ivana Milosevic ⁶⁷ , Fatima Mirás ⁶⁸ , Marta Morawska ^{69 70} , Marina Motta ⁷¹ , Talha Munir ⁷² , Roberta Murru ⁷³ , Carsten U Niemann ⁴⁰ , Raquel Nunes Rodrigues ⁴¹ , Jacopo Olivieri ⁷⁴ , Lorella Orsucci ⁷⁵ , Maria Papaioannou ¹⁶ , Miguel Arturo Pavlovsky ⁷⁶ , Inga Piskunova ⁷⁷ , Viola Maria Popov ⁷⁸ , Francesca Maria Quaglia ⁷⁹ , Giulia Quaresmini ⁸⁰ , Kristian Qvist ⁸¹ , Gianluigi Reda ⁸² , Gian Matteo Rigolin ⁸³ , Rosa Ruchlemer ⁸⁴ , Gevorg Saghumyan ⁴⁴ , Amit Shrestha ⁸⁵ , Martin Šimkovič ⁸⁶ , Martin Špaček ⁸⁷ , Paolo Sportoletti ⁸⁸ , Oana Stanca ⁸⁹ , Niki Stavroyianni ¹ , Tamar Tadmor ⁹⁰ , Doreen Te Raa ⁹¹ , Sanne H Tonino ⁹² , Livio Trentin ⁹³ , Ellen Van Der Spek ⁹⁴ , Michel van Gelder ⁹⁵ , Roel van Kampen ⁹⁶ , Marzia Varettoni ⁹⁷ , Andrea Visentin ⁹³ , Candida Vitale ⁹⁸ , Ewa Wasik-Szczepanek ⁹⁹ , Tomasz Wróbel ⁵³ , Lucrecia Yáñez San Segundo ¹⁰⁰ , Mohamed Yassin ¹⁰¹ , Marta Coscia ⁹⁸ , Alessandro Rambaldi ^{80 102} , Emili Montserrat ¹⁸ , Robin Foà ⁶⁶ , Antonio Cuneo ⁸³ , Kostas Stamatopoulos ¹⁰³ , Paolo Ghia ^{# 104}



Affiliations

• PMID: 34725454
• DOI: 10.1038/s41375-021-01450-8

Abstract

Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p < 0.001). Untreated patients had a lower risk of death (HR = 0.54, 95% CI:0.41-0.72). The risk of death was higher for older patients and those suffering from cardiac failure (HR = 1.03, 95% CI:1.02-1.04; HR = 1.79, 95% CI:1.04-3.07, respectively). Age, CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival than those on treatment or recently treated.